Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Chemotherapy and IL-2 Activated PBSC for Solid Tumors and Lymphoma
NCT00027937Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Aug 2001
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aldesleukin in solid tumor, Hodgkin lymphoma (HL) and B-cell non-Hodgkin lymphoma, sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Toxicity of regimen. Started Aug 2001; status: completed.
02
Drugs
aldesleukin
03
Conditions
solid tumorHodgkin lymphoma (HL)B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT00027937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00027937.